Related Experiment Video

Updated: Feb 26, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K

Gene polymorphism of xenobiotic detoxification in children with bronchial asthma

Liudmila Y Lytvynets1

  • 1Departament of Pediatrics, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine.

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|July 18, 2017
PubMed

Insights

Genetic variations in xenobiotic detoxification genes influence childhood asthma development and severity. Specific microsomal epoxide hydrolase (mEPHX1) genotypes are linked to uncontrolled asthma and altered enzyme activity in children.

Area of Science:

  • Environmental Health
  • Pediatric Pulmonology
  • Genetic Epidemiology

Background:

  • Children's developing systems are highly susceptible to environmental toxins.
  • Chronic respiratory diseases, particularly bronchial asthma, are significant health concerns in children, often linked to environmental pollutants.
  • Investigating the interplay of genetic and environmental factors in childhood asthma pathogenesis is crucial.

Purpose of the Study:

  • To investigate the phenotypic characteristics of bronchial asthma in children from the Pre-Carpathian region.
  • To examine the association between allelic gene polymorphism of microsomal epoxide hydrolase 1 (mEPHX1) and asthma.
  • To understand how xenobiotic detoxification gene variants influence asthma susceptibility and severity in pediatric populations.

Main Methods:

  • Studied 94 children with bronchial asthma from the Ivano-Frankivsk region.
  • Analyzed DNA isolated from peripheral blood leukocytes using commercial kits.
  • Investigated the association between mEPHX1 gene polymorphism and the occurrence and severity of bronchial asthma.

Main Results:

  • Specific genotypes (CC and GG) of mEPHX1 were significantly more frequent in children with uncontrolled asthma (p <0.05).
  • Children with asthma frequently exhibited high enzymatic activity associated with mEPHX1 polymorphic variants (AG, AA-TT-TT).
  • A 'slow' functional state of mEPHX1, indicated by specific homozygous and heterozygous genotypes (CC-AA, TC-AA), was also common.

Conclusions:

  • Individual variations in the metabolic activity of xenobiotic detoxification genes, specifically mEPHX1, impact the eco-determined manifestation of bronchial asthma.
  • The study highlights the role of genetic polymorphisms in mEPHX1 in influencing asthma phenotypes and severity in children.
Abstract

Keywords:
childrenbronchial asthmagenes of xenobiotic detoxification

More Related Videos

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

6.6K
Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

11.7K

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
36
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
57
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
41
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
289